Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
171,717,172
-
Number of holders
-
130
-
Total 13F shares, excl. options
-
112,991,648
-
Shares change
-
+2,204,914
-
Total reported value, excl. options
-
$3,381,093,020
-
Value change
-
+$65,326,181
-
Put/Call ratio
-
91.73%
-
Number of buys
-
62
-
Number of sells
-
-50
-
Price
-
$29.93
Significant Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) as of Q1 2022
151 filings reported holding RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2022.
Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 112,991,648 shares
of 171,717,172 outstanding shares and own 65.8% of the company stock.
Largest 10 shareholders include SB INVESTMENT ADVISERS (UK) LTD (27,904,963 shares), FMR LLC (16,242,006 shares), VANGUARD GROUP INC (6,217,623 shares), BlackRock Inc. (5,974,183 shares), PRICE T ROWE ASSOCIATES INC /MD/ (4,999,718 shares), BVF INC/IL (4,530,605 shares), DRIEHAUS CAPITAL MANAGEMENT LLC (4,050,688 shares), Bellevue Group AG (3,918,962 shares), Casdin Capital, LLC (3,857,253 shares), and JPMORGAN CHASE & CO (3,274,389 shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.